Coppell Advisory Solutions LLC Buys New Position in NovoCure Limited $NVCR

Coppell Advisory Solutions LLC purchased a new position in shares of NovoCure Limited (NASDAQ:NVCR) during the 2nd quarter, Holdings Channel reports. The institutional investor purchased 38,953 shares of the medical equipment provider’s stock, valued at approximately $590,000.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. First Bancorp Inc ME purchased a new position in NovoCure in the 2nd quarter worth approximately $38,000. Empowered Funds LLC acquired a new position in shares of NovoCure during the fourth quarter worth $33,000. Kestra Advisory Services LLC acquired a new position in shares of NovoCure during the fourth quarter worth $49,000. Larson Financial Group LLC lifted its position in shares of NovoCure by 662.1% during the third quarter. Larson Financial Group LLC now owns 4,100 shares of the medical equipment provider’s stock worth $53,000 after purchasing an additional 3,562 shares in the last quarter. Finally, Headlands Technologies LLC purchased a new position in shares of NovoCure in the second quarter valued at $88,000. Hedge funds and other institutional investors own 84.61% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on NVCR shares. Wedbush raised their price target on shares of NovoCure from $18.00 to $20.00 and gave the company a “neutral” rating in a report on Friday, July 24th. Wall Street Zen cut shares of NovoCure from a “buy” rating to a “hold” rating in a research report on Saturday, August 29th. JPMorgan Chase & Co. assumed coverage on NovoCure in a research note on Monday, July 13th. They set a “neutral” rating and a $17.00 target price for the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of NovoCure in a research report on Thursday, August 27th. Finally, HC Wainwright set a $32.00 target price on NovoCure in a research report on Friday, July 24th. Two investment analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $21.20.

NovoCure Stock Performance

NovoCure stock opened at $17.64 on Friday. The stock has a market cap of $2.05 billion, a P/E ratio of -13.57 and a beta of 1.01. The company has a current ratio of 2.89, a quick ratio of 2.70 and a debt-to-equity ratio of 0.58. The stock has a 50 day moving average of $16.78 and a 200-day moving average of $15.01. NovoCure Limited has a 52 week low of $9.82 and a 52 week high of $21.45.

NovoCure (NASDAQ:NVCR) last issued its quarterly earnings results on Thursday, July 23rd. The medical equipment provider reported ($0.13) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.33) by $0.20. The business had revenue of $183.58 million during the quarter, compared to analyst estimates of $172.44 million. NovoCure had a negative net margin of 21.25% and a negative return on equity of 44.00%. The business’s revenue was up 15.6% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.36) earnings per share. On average, analysts expect that NovoCure Limited will post -1.21 EPS for the current fiscal year.

NovoCure Profile

NovoCure is a global oncology company pioneering Tumor Treating Fields (TTFields), a novel anti-mitotic therapy for solid tumors. The company’s non-invasive treatment platforms deliver low-intensity, alternating electric fields designed to disrupt cancer cell division. NovoCure’s approach offers an alternative modality to complement existing therapies in oncology, with a focus on hard-to-treat malignancies.

Founded in 2000 and headquartered in Haifa, Israel, NovoCure maintains a second operational center in Portsmouth, New Hampshire.